- All dermatological conditions among intensive care unit patients (N=365).
| Categories | n (%) | % all dermatological conditions | ||||
|---|---|---|---|---|---|---|
| Inflammatory and autoimmune diseases | ||||||
| Dermatitis or eczema | 14 (28.0) | 3.8% | ||||
| Intertrigo | 9 (18.0) | 2.5% | ||||
| Prurigo | 7 (14.0) | 1.9% | ||||
| Urticaria | 4 (8.0) | 1.1% | ||||
| Folliculitis | 3 (6.0) | 0.8% | ||||
| Alopecia areata | 2 (4.0) | 0.5% | ||||
| Panniculitis | 2 (4.0) | 0.5% | ||||
| Acne vulgaris | 2 (4.0) | 0.5% | ||||
| Erythema multiforme | 1 (2.0) | 0.3% | ||||
| Pyoderma gangrenosum | 1 (2.0) | 0.3% | ||||
| Erythroderma | 1 (2.0) | 0.3% | ||||
| Id reaction | 1 (2.0) | 0.3% | ||||
| Lichen planus | 1 (2.0) | 0.3% | ||||
| Psoriasis | 1 (2.0) | 0.3% | ||||
| GVHD | 1 (2.0) | 0.3% | ||||
| Connective tissue diseases | ||||||
| Lupus erythematosus | 4 (66.7) | 1.1% | ||||
| Dermatomyositis | 1 (16.7) | 0.3% | ||||
| Mixed connective tissue disease | 1 (16.7) | 0.3% | ||||
| Immunobullous | ||||||
| Bullous pemphigoid | 7 (70.0) | 1.9% | ||||
| Epidermolysis bullosa acquisita | 3 (30.0) | 0.8% | ||||
| Infections | ||||||
| Bacterial | ||||||
| Cellulitis | 4 (22.2) | 1.1% | ||||
| Ecthyma or ecthyma gangrenosum | 3 (16.7) | 0.8% | ||||
| Bullous impetigo | 2 (11.1) | 0.5% | ||||
| Skin abscesses | 2 (11.1) | 0.5% | ||||
| Staphylococcal scalded skin syndrome | 2 (11.1) | 0.5% | ||||
| Necrotizing fasciitis | 1 (5.6) | 0.3% | ||||
| Toxic shock syndrome | 1 (5.6) | 0.3% | ||||
| Unclassified bacterial infection | 3 (16.7) | 0.8% | ||||
| Fungal | ||||||
| Candidiasis | 14 (66.7) | 3.8% | ||||
| Dermatophytosis | 5 (23.8) | 1.4% | ||||
| Unclassified fungal infection | 2 (9.5) | 0.5% | ||||
| Viral | ||||||
| Herpes zoster | 17 (54.8) | 4.7% | ||||
| Herpes simplex virus | 9 (29.0) | 2.5% | ||||
| Warts | 2 (6.5) | 0.5% | ||||
| Viral exanthem | 2 (6.5) | 0.5% | ||||
| Cutaneous CMV | 1 (3.2) | 0.3% | ||||
| Parasitic | ||||||
| Scabies | 1 (100) | 0.3% | ||||
| Drug reactions | ||||||
| Severe cutaneous drug adverse reactions | ||||||
| SJS/TEN | 7 (50.0) | 1.9% | ||||
| Acute generalized exanthematous pustulosis | 5 (35.7) | 1.4% | ||||
| DRESS syndrome | 2 (14.3) | 0.5% | ||||
| Other drug reactions | ||||||
| Morbilliform drug eruption | 25 (52.1) | 6.8% | ||||
| Drug induced acne | 6 (12.5) | 1.6% | ||||
| Bullous drug eruption | 3 (6.3) | 0.8% | ||||
| SDRIFE | 2 (4.2) | 0.5% | ||||
| Fixed drug eruption | 1 (2.1) | 0.3% | ||||
| Toxic erythema of chemotherapy | 1 (2.1) | 0.3% | ||||
| Warfarin necrosis | 1 (2.1) | 0.3% | ||||
| Unclassified drug reaction | 9 (18.8) | 2.5% | ||||
| Categories | n (%) | % all dermatological conditions |
|---|---|---|
| Dermatoses due to exogenous factors | ||
| Contact dermatitis | 23 (46.0) | 6.3% |
| Bed sores | 8 (16.0) | 2.2% |
| Trauma induced ulcer or blister | 7 (14.0) | 1.9% |
| Pressure induced alopecia | 4 (8.0) | 1.1% |
| Hematoma | 2 (4.0) | 0.5% |
| Burn | 2 (4.0) | 0.5% |
| Extravasation | 2 (4.0) | 0.5% |
| Pressure induced erythema | 1 (2.0) | 0.3% |
| Trauma induced nail dystrophy | 1 (2.0) | 0.3% |
| Vascular and coagulopathies | ||
| Vasculitis | 20 (46.5) | 5.5% |
| Purpura due to thrombocytopenia | 14 (32.6) | 3.8% |
| DIC, purpura fulminans | 4 (9.3) | 1.1% |
| Ischemic skin changes or necrosis | 3 (7.0) | 0.8% |
| Superficial thrombophlebitis | 1 (2.3) | 0.3% |
| Lymphedema | 1 (2.3) | 0.3% |
| Congenital and neonatal skin disorders | ||
| Infantile hemangioma | 10 (26.3) | 2.7% |
| Port wine stain | 8 (21.1) | 2.2% |
| Aplasia cutis congenita | 4 (10.5) | 1.1% |
| Nevus sebaceous | 4 (10.5) | 1.1% |
| Ichthyosis | 3 (7.9) | 0.8% |
| Collodion baby | 2 (5.3) | 0.5% |
| Mongolian spots | 2 (5.3) | 0.5% |
| Acrodermatitis enteropathica -like eruption | 1 (2.6) | 0.3% |
| Klippel-Trenaunay syndrome | 1 (2.6) | 0.3% |
| Neonatal cephalic pustulosis | 1 (2.6) | 0.3% |
| Stiff skin syndrome | 1 (2.6) | 0.3% |
| Subcutaneous fat necrosis of the newborn | 1 (2.6) | 0.3% |
| Neoplasms | ||
| Kaposi sarcoma | 1 (25.0) | 0.3% |
| Lymphoma | 1 (25.0) | 0.3% |
| Seborrheic keratosis | 1 (25.0) | 0.3% |
| Squamous cell carcinoma | 1 (25.0) | 0.3% |
| Miscellaneous | ||
| Miliaria | 7 (25.0) | 1.9% |
| Edema bullae | 6 (21.4) | 1.6% |
| Xerosis | 5 (17.9) | 1.4% |
| Calcinosis cutis | 3 (10.7) | 0.8% |
| Hyperkeratosis | 3 (10.7) | 0.8% |
| Acquired perforating dermatosis | 2 (7.1) | 0.5% |
| Bullosis diabeticorum | 1 (3.6) | 0.3% |
| Post inflammatory pigmentary changes | 1 (3.6) | 0.3% |
| Unclear diagnosis | 3 (100) | 0.8% |
Values are presented as numbers and percentages (%). CMV: cytomegalovirus,
DIC: disseminated intravascular coagulation, DRESS: drug reaction with eosinophilia and systemic symptoms, GVHD: graft-versus-host disease, SDRIFE: symmetrical drug-related intertriginous and flexural exanthema, SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis